Industry attorneys and health consultants are predicting a new policy climate in Washington for health care regulations following the Nov. 8 elections and the choice of Donald Trump as president; one of the first policies to be impacted by the new approach, is a pending laboratory-developed test oversight framework from FDA.
"Certainly a focus of the Trump campaign was reducing regulation on industry, so I do believe there will be a new FDA, overall affecting the medical device industry, but also...